Jaguar Health, Inc. (JAGX): Results of Operations and Financial Condition
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Second Quarter 2026 Financials Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced , presentation at ESPGHAN 2026 described additional groundbreaking re
How this was made
The 30-second read
Why it matters
Earnings miss and increased net loss pressure the stock, but the upfront licensing payment and holdback provide near‑term liquidity.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders focused on biotech earnings and licensing cash flows.
What to watch
Potential future revenue from the upcoming MVID NDA submission and possible additional grant funding.
Background
Jaguar Health announced Q2 2026 financials via an SEC Form 8‑K, detailing revenue, expenses, and a new U.S. licensing agreement with Future Pak.
Ticker impact
Jaguar Health filed an 8‑K reporting Q2 2026 results, including a 60% drop in product revenue and a net loss of $12.7 M.
Potential near‑term downside of 5‑10% unless the licensing cash inflow offsets earnings weakness.
Earnings miss and higher losses are material for a micro‑cap; however, the $2 M holdback and $16 M upfront license payment provide some cushion.
Market effects
Highlights challenges in niche biotech licensing models and may affect peer rare‑disease companies.
Limited to US biotech microcaps; no broader regional effect.
Minimal global impact beyond niche investors.
Counterpoint
The licensing cash could fund upcoming NDA filing, offering upside if clinical data succeed.
Key entities
- companyJaguar Health, Inc.
NASDAQ‑listed biotech developing crofelemer for rare intestinal failure diseases.
- partnerFuture Pak, LLC
Exclusive U.S. marketer for Jaguar's Mytesi and Canalevia products under a licensing deal.
